DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk - LARVOL DELTA

Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study. (PubMed, Endocr Regul) - "IDegAsp can provide a significant decrease in HbA1c in a real-life setting. Although weight gain was observed in the first months of the treatment, this effect disappeared over time and decreased to the baseline levels."

Journal • Observational data • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. (PubMed, Drug Des Devel Ther) - "The adverse events (AEs) of hypokalemia and hypoglycemia were identified as treatment-related AEs (TRAEs) and all TRAEs were mild. This study demonstrated the PK equivalence of the two drugs and confirmed that both were well-tolerated."

Clinical • Journal • P1 data • PK/PD data • Hypoglycemia

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies. (PubMed, Diabetes Obes Metab) - "Once-daily iGlarLixi was associated with superior blood glucose control and body weight benefit compared with IDegAsp in insulin-experienced populations with T2D in non-Asian RCTs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Clinical • Retrospective data • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers. (PubMed, Expert Opin Investig Drugs) - "Adverse events were similar for both products and no significant safety concerns were noted in the laboratory results, vital signs, or electrocardiogram. This study demonstrated the PK/PD similarity of 22,011 to Ryzodeg with a comparable safety profile."

Journal • PK/PD data

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (clinicaltrials.gov) - P2 | N=153 | Completed | Sponsor: Gan and Lee Pharmaceuticals, USA | Enrolling by invitation ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study. (PubMed, World J Diabetes) - "The present findings suggest that treatment with IDegAsp enhances clinical outcomes, particularly FBG levels, daily cumulative insulin dose, and overall satisfaction with diabetes treatment."

Clinical • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Treatment included an insulin-dextrose infusion until DKA resolved, followed by twice daily insulin degludec/aspart (Ryzodeg 70/30) and metformin. The PPK was attributed likely secondary to sub-optimally managed diabetes. Diabetes mellitus has multiple complications, including rare dermatologic manifestations such as PPK.This case illustrates the importance of thorough skin assessments in patients with diabetes, particularly those that have a history of sub-optimal diabetes control.A multidisciplinary approach, integrating dermatology, endocrinology and allied health services such as podiatry, is essential in managing diabetes-related complications, improving patient quality of life and preventing further complex manifestations."

Journal • Dermatology • Diabetes • Endocrine Disorders • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China. (PubMed, Diabetes Obes Metab) - "In a broad, real-world Chinese population of adults with T2D, initiating or switching to IDegAsp was associated with improved glycaemic control and lower rates of hypoglycaemia. The use of IDegAsp could be an effective treatment option for those with suboptimal glycaemic control or therapeutic inertia."

Journal • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study. (PubMed, J ASEAN Fed Endocr Soc) - "Initiating or switching to IDegAsp was associated with improved glycemic control, lower body weight, and lower HRU for people with T2D in the Philippines. No new, unexpected AEs were reported."

Journal • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors. (PubMed, Medicine (Baltimore)) - "This study aims to investigate the fear and compliance of Insulin Degludec and Insulin Aspart (IDegAsp) injection in type 2 diabetes mellitus (T2DM) patients and study the factors influencing patient compliance. Educational level, disease duration, complications, cognitive level, self-efficacy level, comorbidity count, and living status are important factors affecting the fear and treatment compliance of IDegAsp injection in T2DM patients. These findings have implications for improving patient compliance and alleviating treatment fear."

Compliance • Journal • Observational data • Cognitive Disorders • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study. (PubMed, J Family Med Prim Care) - P | "This was accompanied by a numerical reduction in resource utilization and patient-reported hypoglycaemia. Clinical trial registration: NCT04042441."

Journal • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing. (PubMed, Diabetes Ther) - "In the setting of transition to IDegAsp from premixed insulin, the dose of basal insulin in the premixed formulation can be a valuable reference for adjusting insulin degludec dose. IDegAsp is superior to premixed insulin in blood glucose control with reduced total daily dose and injection frequency. IDegAsp could be the best choice for the management of diabetes in elderly patients."

Journal • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drug(s): the SoliD randomised controlled trial (EASD 2024) - P3 | "Background and aims: SoliD compared the efficacy and safety of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, vs insulin degludec + insulin aspart (IDegAsp) in Chinese people with T2D suboptimally controlled with oral antidiabetic drug(s) (OAD). Materials and In this 24-week, multicentre, open-label, phase 3 study, insulin-naïve people with HbA 1c 7-11% were randomised 1:1 to once-daily iGlarLixi (n=291) or IDegAsp (n=291), with continued metformin ± sodium-glucose co-transporter-2 inhibitors... In Chinese people with T2D, suboptimally controlled on OAD(s), iGlarLixi achieved superior improvements in glycaemic control, prevention of BW gain and a lower hypoglycaemic event rate vs IDegAsp"

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional study. (PubMed, Intern Med J) - "Initiating or switching to IDegAsp in a real-world population of people with T2D in Australia was associated with significant improvements in glycaemic control and body weight, and numerically lower levels of hypoglycaemia compared with baseline."

Journal • Observational data • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) in a Real-World Setting in China (ADA 2024) - P | "Initiating/switching to IDegAsp improved glycemic control in a real-world population of Chinese adults with T2D."

Clinical • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

A Prospective Study on Switching from Basal Insulin to Insulin Degludec/Insulin Aspart, in Patients with Type 2 Diabetes Whose FPG Levels Are Lower Than Those Predicted by Their HbA1c (ADA 2024) - "Compared to basal insulin, once-daily IDegAsp demonstrated a marginal benefit in reducing HbA1c in patients with lower FPG than predicted by their HbA1c, though the glycemic excursions after breakfast were significantly improved. More indices would be needed to tell those expected to have significant benefits by switching from basal insulin to IDegAsp. UTN#: U1111-1241-6269"

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

A Novel Premix Insulin GZR101 for Diabetes Management (ADA 2024) - "Potency was tested in vivo in streptozotocin-induced T1DM rats and db/db T2DM mice, using insulin degludec (iDeg) and iDegAsp as controls. Traditional basal insulins display a 24-hour glucose-lowering effect with noticeable peaks, leading to fluctuating blood glucose in patients. However, a basal insulin with over 3-day longevity and once-daily dosing, like GZR33, can achieve a nearly peak-less PK profile at steady-state. Consequently, GZR101 emerges as a promising once-daily premix insulin candidate."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • IR

Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial (ADA 2024) - P3 | "Funding By Sanofi Introduction and Objective: SoliD (NCT05413369) compared the efficacy and safety of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, vs insulin degludec + insulin aspart (IDegAsp) in Chinese people with T2D suboptimally controlled with OAD(s). In this 24-week, multicenter, open-label, Phase 3 study, insulin-naïve people with HbA1c 7-11% were randomized 1:1 to once-daily iGlarLixi (n=291) or IDegAsp (n=291), with continued metformin ± sodium-glucose co-transporter-2 inhibitors... In Chinese people with T2D, suboptimally controlled on OAD(s), iGlarLixi achieved superior improvements in glycemic control, prevention of BW gain and a lower hypoglycemic event rate vs IDegAsp."

Clinical • Late-breaking abstract • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin—A Systemic Literature Review and Network Meta-analysis (ADA 2024) - "Funding By Funded by Sanofi Introduction and Objective: The objective of this systematic review and network meta-analysis (NMA) was to estimate the relative treatment effect of iGlarLixi (insulin glargine 100 U/mL + lixisenatide) versus premixed insulin IDegAsp (insulin degludec + insulin aspart) in people with T2D inadequately controlled with basal insulin (BI). A systematic review identified recently published randomized controlled trials (RCTs) by searching Embase (including congress abstracts from 2021-2023), MEDLINE, and CENTRAL in October 2023... Treatment with iGlarLixi versus premix IDegAsp was associated with a greater reduction in HbA1c, PPG, and morning and afternoon SMPG, with less weight gain and lower insulin dose."

Late-breaking abstract • Retrospective data • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial. (PubMed, Diabetes Obes Metab) - "In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. (PubMed, Iran J Public Health) - "However, there was no significant difference in the improvement of body weight change (P=0.99), glycosylated hemoglobin (P=0.50), the overall risk of hypoglycemic events (P=0.57) and adverse events (P=0.89) between the two groups. Compared with BIAsp30, IDegAsp could significantly reduce FPG levels, insulin dosage, and the risk of nocturnal hypoglycemic events in T2D patients, without increasing the overall risk of adverse events."

Journal • Retrospective data • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins. (PubMed, Intern Med J) - "Inpatients treated with IDegAsp compared to BIAsp30 had similar hypoglycaemia incidence, but higher hyperglycaemia incidence, potentially related to less frequent twice-daily dosing. With the increasing use of IDegAsp in the community, development of hospital management guidelines for this insulin formulation is needed."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes. (PubMed, Diabetol Int) - "Once-daily IDegLira had greater effects on HbA1c and a lesser increase in insulin doses than IDegAsp when patients are switched from basal insulin therapy. Moreover, the effect on HbA1c was enhanced in patients with high HbA1c levels at baseline."

Journal • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus. (PubMed, Diabetes Metab J) - P=N/A | "The rates of overall and severe hypoglycemia were similar in the two periods. In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin."

Journal • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus